Raquel Palao

Dr. Raquel Palao

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Acta Biomaterialia
Verified
Journal Article
Closed access
SMSergio Martín-Saldaña
Sergio Martín-Saldaña
RPRaquel Palao
Raquel Palao
MAMaría Rosa Aguilar De Armas
María Rosa Aguilar De Armas
RRRafael Ramírez-Camacho
Rafael Ramírez-Camacho
JRJulio San Román
Julio San Román

1 February 2016 in Progress in Polymer Science
Verified
Journal Article
Closed access
RPRaquel Palao
Raquel Palao
LGLaura G. Gómez-Mascaraque
Laura G. Gómez-Mascaraque
MAM.R. Aguilar
M.R. Aguilar
BVBlanca Vázquez-Lasa
Blanca Vázquez-Lasa
JRJ. San Román
J. San Román

22 April 2015 in Biomacromolecules
Verified
Journal Article
Closed access
RPRaquel Palao
Raquel Palao
MAMaría Rosa Aguilar De Armas
María Rosa Aguilar De Armas
FPFrancisco J. Parra-Ruiz
Francisco J. Parra-Ruiz
MGMar Fernandez Gutierrez
Mar Fernandez Gutierrez
JPJuan Parra
Juan Parra
JRJulio San Román
Julio San Román

1 May 2016 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SSSergio Martin Saldaña
Sergio Martin Saldaña
RPRaquel Palao
Raquel Palao
ATAlmudena Trinidad
Almudena Trinidad
MAMaría Rosa Aguilar De Armas
María Rosa Aguilar De Armas
RRRafael Ramírez-Camacho
Rafael Ramírez-Camacho
JRJulio San Román
Julio San Román

1 January 2021 in Drug Delivery
Verified
Journal Article
Open access
JRJuan Riestra-Ayora
Juan Riestra-Ayora
CSCarolina Sánchez-Rodríguez
Carolina Sánchez-Rodríguez
RPRaquel Palao
Raquel Palao
JYJoaquín Yanes-Díaz
Joaquín Yanes-Díaz
AMAna Martín-Hita
Ana Martín-Hita
RSRicardo Sanz-Fernández
Ricardo Sanz-Fernández
The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) is generally poor. New treatments are required to supplement the current standard of care. Paclitaxel (PTX), an effective chemotherapeutic for HNSCC, has serious side effects. A polymeric nanocarrier system was developed for the delivery of PTX to improve HNSCC treatment. This study aimed to evaluate the antitumor efficacy of PTX-loaded polymeric nanoparticles based on α-TOS (PTX-NPs) administered by direct intratumoral injection into a Hypopharynx carcinoma squamous cells (FaDu) tumor xenograft mouse model. The nanocarrier system based on block copolymers of polyethylene glycol (PEG) and a methacrylic derivative of α-TOS was synthesized and PTX was loaded into the delivery system. Tumor volume was measured to evaluate the antitumor effect of the PTX-NPs. The relative mechanisms of apoptosis, cell proliferation, growth, angiogenesis, and oxidative and nitrosative stress were detected by Western blotting, fluorescent probes, and immunohistochemical analysis. The antitumor activity results showed that compared to free PTX, PTX-NPs exhibited much higher antitumor efficacy and apoptosis-inducing in a FaDu mouse xenograft model and demonstrated an improved safety profile. Ki-67, EGFR, and angiogenesis markers (Factor VIII, CD31, and CD34) expression were significantly lower in the PTX-NPs group compared with other groups (p < .05). Also, PTX-NPs induced oxidative and nitrosative stress in tumor tissue. Direct administration of PTX-loaded polymeric nanoparticles based on α-Tocopheryl Succinate at the tumor sites, proved to be promising for HNSCC therapy.

19 September 2018 in Biomolecules
Verified
Journal Article
Open access
PDF file
CSCarolina Sánchez-Rodríguez
Carolina Sánchez-Rodríguez
RPRaquel Palao
Raquel Palao
LRLaura Rodrigáñez
Laura Rodrigáñez
MAMaría Rosa Aguilar De Armas
María Rosa Aguilar De Armas
SSSergio Martin Saldaña
Sergio Martin Saldaña
RSRicardo Sanz-Fernández
Ricardo Sanz-Fernández
The aim of this work is to study, in an in vitro head and neck squamous cell carcinomas model the anti-angiogenic and anti-migratory properties of self-assembled polymeric nanoparticles (NPs) with demonstrated selective anticancer activity. The NPs are based on α-tocopheryl succinate (α-TOS) encapsulated in the hydrophobic core of the NPs. We analyzed the effect of the newly synthetized α-TOS-loaded NPs in proliferating endothelial cells and hypopharynx carcinoma squamous cells and measured markers of angiogenesis, apoptosis and reactive oxygen species (ROS). α-TOS-loaded NPs suppressed angiogenesis by inducing accumulation of ROS and inducing apoptosis of proliferating endothelial cells. These NPs also decrease the number and quality of capillary-like tubes in an in vitro three-dimensional (3D) experiment, decrease the production of the pro-angiogenic vascular endothelial growth factor and down-regulate the expression of its receptor. The anti-migratory efficacy of α-TOS is corroborated in hypopharynx carcinoma cells by decreasing the secretion of matrix metalloproteases 2 and 9 (MMP-2 and MMP-9) and inhibiting cell migration. These results confirm that α-TOS-based NPs not only present anticancer properties, but also antiangiogenic properties, therefore making them promising candidates for multi-active combinatorial anticancer therapy.